



3415A 3 Ave NW, Calgary, Alberta, T2N 0M4, Canada

**Patient Name:** Patient, Name**Specimen ID (SID):** 25-001-0000**DOB:** 01-Jan-2000**PHN:** AB 0000000**Reason for Testing:** HLH**Relevant Medications:** -**External SID:** 123456789**Doctor:** Dr. Doctor**Report Date:** 12-Mar-2025**Specimen Type:** Plasma**Date/Time Collected:** 01-Jan-2025 / 00:00**Specimen Source:** MitogenDx**Soluble Cytokine Receptor Panel****Laboratory Developed Test (LDT)**

Analyte	Results (pg/ml)	Reference Interval†
sCD30	< 122	0 - 208
sEGFR	24637	17273 - 55289
sgp130	55919 HIGH	8649 - 54314
sIL-1RI	95.7 HIGH	6.2 - 71.2
sIL-1RII	37455 HIGH	1032 - 10251
sIL-2R α	3322 HIGH	83 - 1815
sIL-4R	< 244	0 - 778
sIL-6R	9087	3356 - 12040
sRAGE	8.9	0 - 20.9
sTNFRI	14348 HIGH	154 - 1829
sTNFRII	44194 HIGH	1578 - 8190
sVEGFR1	371	0 - 1028
sVEGFR2	9999	4570 - 21298
sVEGFR3	< 152	0 - 912

Sample Comments:

-

Results Interpretation:

Possible abnormalities have been detected in TNF family signaling (sTNFRI, sTNFRII), IL-1 signaling (sIL-1RI, sIL-1RII), T cell activation (sIL-2R α), and gp130 family (CNTF, CLCF1, LIF, IL-27, and IL-6) signaling (sgp130).

Disclaimer:

The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.

Reviewed by: DP**Eve Technologies Corporation is a CLIA certified High Complexity International Laboratory**† Reference intervals estimated by data-mining ≥ 1500 PLASMA samples drawn from both healthy and pathological subjects.